ImmuCell to Expand Freeze-Drying Capacity in H1 2027 Following Strategic Shift to First Defense
ImmuCell Corporation (ICCC) has confirmed that its $8 million capacity expansion plan remains on track, with the initial freeze-drying expansion expected to commence in the first half of 2027. This capital expenditure is part of a broader strategic realignment aimed at scaling production capabilities. The company's management, led by CEO P. F. Te Boekhorst, confirmed that ImmuCell has pivoted to focus exclusively on its First Defense product line. Following a decision made in December 2025, the company has ceased all investments into Re-Tain to prioritize supply reliability and resource allocation toward its primary growth driver.
